source
- AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease pushTech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.
- Immunovant halts cutaneous lupus program after phase 2 failureImmunovant announced it is discontinuing development of its anti-FcRn antibody IMVT-1402 for cutaneous lupus erythematosus. The decision follows a mid-phase trial that did not meet its primary end…